NCT00724971 - Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2008

Primary Completion Date

March 10, 2010

Study Completion Date

March 10, 2010

Conditions

Lymphoma, B-Cell

Interventions

DRUG

Inotuzumab Ozogamicin (CMC-544)

1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.

DRUG

Rituximab (Rituxan)

375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.

Trial Locations (4)

Nagoya Daini Red Cross Hospital, Aichi

Tokai University Hospital, Kanagawa

National Cancer Center Hospital, Tokyo

Cancer Inst. Hp. of Japanese Foundation for Cancer Research, Tokyo